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ABSTRACT
Objective: The objective of the study was to develop and validate a rapid selective bioanalytical method for the simultaneous determination of 
metformin and canagliflozin in plasma by liquid chromatography-tandem mass spectrometer (LC-MS/MS) to facilitate bioequivalence study sample 
analysis. Stock solutions and spiking solutions were prepared accurately in methanol and 80% methanol in water, respectively.
Methods: Chromatography monitored using Analyst 1.6.2 software. Method was found selective, no matrix effect, reproducible and consistent 
recovery, accuracy, precision, and stable in aqueous as well as extracted/matrix samples. Method found linear over the range 10–2000 ng/ml for 
metformin and 30–6000 ng/ml for canagliflozin. The method is successfully applied to analyze samples collected in a bioequivalence study after 
administration of metformin/canagliflozin 1000/150 mg to 24 healthy male volunteers.
Results: Extraction was carried out using a simple solid phase extraction using mobile phase elution. 5 µl sample delivered as injection volume in 
1.000 ml/min isocratic mobile phase flow on turbo ion electron spray technique for positive mode on API 4000 MS.
Discussion: Chromatography achieved within 3 min using a mobile phase containing acetonitrile and 10 mM ammonium formate buffer in a ratio 
of 70:30 on chromolith C18 analytical column. Q1/Q3 are 130.1/70.1, 136.3/77.1, 462.2/267.2 (with ammonium adduct), and 466.4/267.1 for 
metformin, metformin D6, canagliflozin, and canagliflozin D4, respectively.
Conclusion: Rapid, sensitive method for the simultaneous estimation of metformin and canagliflozin in plasma by LC-MS/MS is successfully developed, 
validated and applied to analyze 960 unknown samples of a bioequivalence study. Incurred sample reanalysis was revealed great reproducibility.
Keywords: Metformin+canagliflozin, Metformin and canagliflozin in plasma, Bioequivalence of metformin and canagliflozin, Canagliflozin+metformin 
by liquid chromatography-tandem mass spectrometer.
INTRODUCTION
Metformin hydrochloride is chemically N, Ndimethylimidodicarbonimidic 
diamide hydrochloride (1, 1- dimethylbiguanide hydrochloride). 
Canagliflozin is chemically named as (2S,3R,4R,5S,6R)-2-[3-{[5-(4-
fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl) 
oxane-3,4,5-triol. Molecular weight of metformin is 129.2 g/mol and 
molecular weight of canagliflozin is 444.5 g/mol [1].
Metformin and canagliflozin are fixed dose combination antihyperglycemic 
agents to improve glycemic control in diabetes patients; it has million 
dollars market worldwide. Metformin and Canagliflozin both are old 
drugs, and many formulations are available in the market along with 
fixed-dose combination formulations. When we checked at published 
methods, there are plenty of methods reported for the estimation of 
either metformin or canagliflozin in plasma by liquid chromatography-
tandem mass spectrometer (LC-MS/MS) or high-performance liquid 
chromatography (HPLC) or gas chromatography-MS, but no method 
is published for the simultaneous estimation in plasma by LC-MS/MS, 
development of single method is very difficult due to different polarities 
of drugs and other chemical properties. When we see at the structures of 
both, metformin ionizes in positive mode, whereas canagliflozin ionizes 
in negative mode. Devineni et al. reported method individual estimation 
methods for metformin and canagliflozin [2], Attimara et al. reported 
LC-MS method for the simultaneous determination of metformin and 
miglitol in human plasma: Application to pharmacokinetic studies [3], 
Kobuchi et al. reported method for canagliflozin by LC-MS/MS [4] and 
many others have reported either metformin in plasma or canagliflozin 
in plasma [5-21].
Simultaneous estimation one hand reduce the time of analysis to half so 
that the end results will be available early and regulatory submission 
can be done so early to capture the market share, and the other hand it 
reduces the cost of analysis significantly.
The objective of the current work is to develop, validate a simultaneous 
estimation method for the estimation of metformin and canagliflozin 
in human plasma by LC-MS/MS and its application to bioequivalence 
study.
METHODS
Metformin, metformin d6, canagliflozin, and canagliflozin D4 were 
purchased from Vivan life sciences and Clearsyth Labs Pvt. Ltd., Mumbai, 
India. HPLC grade solvents and chemicals were used during analysis, 
whereas the water is taken from the in-house water purification system. 
Hydrophobic lipophilic balance (HLB) 1 cc/30 mg cartridges are from 
Phenominex, USA. LC-MS/MS system consists of ABSciex, API4000 with 
a front-end HPLC from Shimadzu. Analytical column is purchased from 
Merck Millipore, USA. A bioequivalence study was conducted based on 
a Independent Ethics Committee approved the protocol.
Stock solutions were prepared by accurately weighing respective working 
reference standard (STD) on balance, dissolved in methanol, labeled, 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29027
Research Article
94
Asian J Pharm Clin Res, Vol 12, Issue 2, 2019, 93-97
 Puram et al. 
and stored at refrigerated conditions. Working stock dilutions were 
made using 50% methanol in water as diluent. Eight point calibration 
curve (CC) STDs are prepared in screened plasma for the CC range 
10–2000 ng/ml for metformin and 30–6000 ng/ml for canagliflozin. 
Quality control (QC) samples at the lower limit of quantitation (LLOQ), 
lower QC, middle QC, and high QC levels are prepared at 102% to STD 
1, 3 times to STD1, 45% to STD8, and 76% to STD8 in plasma. Required 
buffers, mobile phase, rinsing solutions are prepared as required and 
used up to 3 days. CC STDs and QC samples are bulk spiked and stored 
at −70°C until analysis. Fresh CC STDs are prepared for the evaluation 
for Stability evaluation.
Extraction procedure
To a 0.200 ml plasma sample, 0.050 ml internal STD is added and 
vortexes for proper mixing; then the sample is diluted with 0.500 mL 
water to prevent clogging of cartridges; cartridges are conditioned 
with 1 ml methanol followed by equilibration with 1 ml water; above 
prepared sample is then loaded onto cartridge; cartridges are washed 
with 1 ml water followed by 1 ml 10% Acetonitrile in water; and then 
samples are eluted with 0.500 ml mobile phase.
Instrument conditions
ABSCIEX API4000 Mass spectrometer coupled with Shimadzu LC 
system was utilized for reverse phase chromatography with an Isocretic 
flow at 1.000 mL/min on RP18 Analytical column. Mass spectrometer 
conditions are presented under Table 1.
Integration and quantitation
Data acquired on Sciex analyst 1.6.2 software; automatic integration 
was done for a base to base and optimum integrations, CC is plotted 
with area ratio versus nominal concentrations of CC STDs, unknown 
sample concentrations are back-calculated from plotted curve using the 
formula y=mx+c, weighing factor was 1/x2.
RESULTS AND DISCUSSION
Method development
About 100 ng/ml tuning solution in 90% methanol was prepared from 
stock solution for analyte and internal STD; mass parameters were 
optimized using tuning solution, metformin ions found intense in 
positive mode and no ions found in negative mode, canagliflozin ions 
found intense in negative mode and no ions found in positive mode, but 
our objective is to get both in a single mode; hence, we decided to go for 
adduct form for canagliflozin as it can form ammonium adduct easily, 
adduction of canagliflozin found intense and reproducible. Labeled 
internal STDs are chosen as internal STDs to eliminate matrix effects 
and to get the highest reproducible results; matrix effects are nullified 
when labeled STDs are used. Based on the properties of the drugs 
correlating with ionization, the mobile phase, column conditions were 
optimized, metformin can easily extracted with protein precipitation 
technique but canagliflozin is difficult to extract; hence, we have tested 
for liquid-liquid extraction using polar to non-polar organic solvents 
but failed to good more than 50% recovery for both analytes, so finally 
we moved to solid phase extraction on HLB cartridges, and we got good 
recovery with reproducibility. Interference at retention times, carryover, 
matrix effect, precision, and accuracy tested and few alterations were 
done, and method is finalized. Pre-method validation was conducted 
before initiating method validation; this includes selectivity, carry over, 
precision, and accuracy, linearity, matrix effect, and bench-top stability. 
Weighing and regression method is finalized based on pre-method 
validation results.
Method validation
Method validation is conducted as per in-house STD operating 
procedure which is developed based on the European Medical Agency 
and United States Food and Drugs Administration guidelines on method 
validation. Autosampler carryover, selectivity, sensitivity, recovery, 
precision, accuracy, linearity, ruggedness for column, and analyst 
change, hemolysis and lipemic effect, aqueous, and extracted sample 
stability were evaluated. Method validation parameters, procedures, 
and acceptance are predefined.
Sensitivity
Sensitivity is performed to check the signal difference from baseline 
noise. LLOQ sample from 6 individual plasma lots was analyzed, signal-
to-noise ratio is calculated using software. Sensitivity found always >5. 
Limit of detection is not evaluated due to non-requirement in the 
current study.
Selectivity
Selectivity is performed to check the endogenous/exogenous 
interferences. Selectivity of the method is tested using 10 plasma 
lots including 6 normal, 2 hemolytic, and 3 hyperlipidemic by 
processing one blank, one blank+Internal STD, and one LLOQ sample 
from each individual lot. Percentage of interference at analyte/IS 
Fig. 1: Metformin lower limit of quantitation
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retention times is calculated considering LLOQ area 100. Selectivity 
found acceptable. Sample LLOQ chromatograms are presented 
under Figs. 1 and 2.
Recovery
Recovery of extraction efficiency was tested. Absolute recovery using 
three levels of QC s was tested. QC samples are processed and injected 
along with equivalent pure samples prepared in reconstitution solution; 
mean areas at each QC level are compared. Recovery found >70% with 
consistent and reproducible.
Linearity, precision, and accuracy
Precision and accuracy batch consists of one cc and 24 qC samples at 
four different levels were analyzed. A total of 4 precision and accuracy 
batches were analyzed in two different days for intra- and inter-day 
calculations. CC for both analytes found linear all the times with r>0.99. 
Global statistics are tabulated in Tables 2 and 3.
Ruggedness
Ruggedness of the method is tested for the changes column, analyst, and 
instrument. One precision and accuracy were analyzed by a different 
analyst on different column/different instrument. Results found 
acceptable. Precision found 2–7% whereas accuracy found between 
86% and 109%.
Stability
Stability of analytes and internal STDs is tested in aqueous solutions 
for short-term as well as long-term by injecting a sample from stability 
solution along with comparison solution prepared freshly. Stability of 
processed samples for different storage conditions such as evaporation 
stability, wet extract stability, autosampler stability, and wet extract 
bench top stability was done along with the stability of drugs in plasma 
at different conditions such as benchtop stability, freeze-thaw stability, 
whole blood stability, and long-term stability. Stock solution found 
stable up to 6 h; benchtop stability found acceptable for 6 h, freeze-
Fig. 2: Canagliflozin lower limit of quantitation
Table 1: Mass conditions
Description Q1 Mass Q3 Mass Dwell DP EP CE CXP
Metformin 130.100 71.100 200 60.00 10.00 20.00 13.00
Metformin D6 136.300 77.100 200 32.23 10.00 33.12 6.41
Canagliflozin (ammonium adduct) 462.250 267.200 200 54.00 10.00 24.81 6.00
Canagliflozin D4 (ammonium adduct) 466.400 267.100 200 60.00 10.00 25.00 15.00
Source temperature: 500°C IS voltage: 5000 kV Polarity: Positive Scan type: MRM
DP: Declustering potential, EP: Entrance potential, CE: Collision energy, CXP: Collision exit potential
Table 2: Global statistics of precision and accuracy of metformin
Between‑batch precision and accuracy
Description LLOQQC LQC MQC HQC
Mean±SD 10.1988±0.80233 25.2631±1.07795 807.3190±26.91706 1583.0191±76.30179
Precision (% CV) 7.87 4.27 3.33 4.82
Nominal concentration (ng/ml) 10.533 26.492 817.656 1566.390
% Accuracy 96.83 95.36 98.74 101.06
CV: Coefficient of variation, SD: Standard deviation, LLOQQC: Lower limit of quantitation quality control, LQC: Lower quality control, MQC: Middle-quality control, 
HQC: High-quality control
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thaw stability found stable up to IV cycles, autosampler stability found 
stable up to 52 h, whole blood stability found acceptable for 2 h, and 
long-term stability in plasma found stable for 28 days.
Miscellaneous experiments such as dilution integrity, hemolysis effect, 
lipemic effect, selectivity in the presence of concomitant drugs were 
conducted and found all experiments acceptable.
Application of the method
Validated method has been applied to a bioequivalence study 
involved 24 volunteers, fixed-dose combination formulation of 
metformin and canagliflozin was administered as per independent 
Ethics Committee approved protocol to 24 volunteers in a two way 
crossover design with 7 days washout period, volunteers whoever 
meeting inclusion and exclusion criteria of protocol and whoever 
given informed consent were recruited after successful completion 
of screening tests. Dosing was done under fasting conditions, 
regular blood sampling was done, vitals checked, blood samples 
were centrifuged, and plasma was separated then stored at −70°C 
until sample transfer to the bioanalytical department for analysis. 
No adverse events were reported, and all 24 volunteers completed 
the clinical phase of the study. All samples of a given subject were 
analyzed using 8 point CC and interspersing QC samples. Batch 
evaluation was conducted and samples selected for repeat analysis 
for analytical reasons, no batch failures found, 22 individual samples 
were reanalyzed for an improper internal STD response. Incurred 
sample reanalysis (ISR) was conducted for 10% samples, 95% 
samples ISR values are matching with original assay value. After 
completion of the analysis, quality assurance department reviewed 
that subject concentration data are submitted to biostatistician in a 
locked Microsoft Excel file. Statistician conducted pharmacokinetic 
analysis on win online, and biostatistician analysis is on SAS 
software. Non-compartmental analysis is done to check 90% 
confidence intervals for bioequivalence review. 90% confidence 
intervals found between 80% and 125% for a test when compared to 
reference formulation. Mean Cmax found is 1256 ng/ml for metformin 
and 390 ng/ml for canagliflozin.
CONCLUSION
Rapid, sensitive method for the simultaneous estimation of metformin 
and canagliflozin in plasma by LC-MS/MS is successfully developed, 
validated and applied to bioequivalence study sample analysis. 
Chromatography achieved on the C18 column on acetonitrile, 
ammonium formate mobile phase, extraction was conducted using 
solid phase extraction on HLB cartridges. Positive MRM detection was 
performed on API 4000 LC-MS/MS. The analysis is rapid with 3 min run 
time for each sample, around 200 samples can be analyzed daily, the 
method found selective from endogenous/exogenous interferences; 
all validation parameters proved that the method is accurate, precise, 
and stable. Method found linear over the range 10–2000 ng/ml for 
metformin and 30–6000 ng/ml for canagliflozin. The method is 
applied to analyze 960 unknown samples of a bioequivalence study 
after administration of a fixed-dose combination of metformin and 
canagliflozin tablets. ISR was revealed great reproducibility with 
over 90% ISR sample concentrations matching with original assay 
concentrations.
Table 3: Global statistics of precision and accuracy of canagliflozin
Between‑batch precision and accuracy
Description LLOQQC LQC MQC HQC
Mean±SD 29.9213±1.30406 74.6727±2.19700 2405.5809±89.89150 4702.9788±165.34826
Precision (% CV) 4.36 2.94 3.74 3.52
Nominal concentration (ng/ml) 31.187 78.437 2420.894 4637.728
% Accuracy 95.94 95.20 99.37 101.41
CV: Coefficient of variation, SD: Standard deviation, LLOQQC: Lower limit of quantitation quality control, LQC: Lower quality control, MQC: Middle-quality control, 
HQC: High-quality control
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